Medlab Clinical (ASX:MDC) Gross Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Medlab Clinical Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Medlab Clinical's Gross Profit for the six months ended in Dec. 2023 was A$0.05 Mil. Medlab Clinical's Revenue for the six months ended in Dec. 2023 was A$0.05 Mil. Therefore, Medlab Clinical's Gross Margin % for the quarter that ended in Dec. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.

The historical rank and industry rank for Medlab Clinical's Gross Margin % or its related term are showing as below:

ASX:MDC' s Gross Margin % Range Over the Past 10 Years
Min: 1.54 Med: 48.72 Max: 89.91
Current: 83.92

During the past 8 years, the highest Gross Margin % of Medlab Clinical was 89.91%. The lowest was 1.54%. And the median was 48.72%.

ASX:MDC's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 60.91 vs ASX:MDC: 83.92

Medlab Clinical had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Medlab Clinical was 23.80% per year.

Medlab Clinical Gross Margin % Historical Data

The historical data trend for Medlab Clinical's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical Gross Margin % Chart

Medlab Clinical Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Gross Margin %

Get a 7-Day Free Trial

43.59

1.54

33.19

73.79

89.91

Medlab Clinical Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross Margin %	Get a 7-Day Free Trial												72.87	74.29	94.15	81.29	-

Competitive Comparison of Medlab Clinical's Gross Margin %

For the Biotechnology subindustry, Medlab Clinical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medlab Clinical's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's Gross Margin % falls into.

Medlab Clinical Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Medlab Clinical's Gross Margin for the fiscal year that ended in Jun. 2023 is calculated as

Gross Margin % (A: Jun. 2023 )	=	Gross Profit (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	0.8	/	0.892
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.892 - 0.09)	/	0.892
	=	89.91 %

Medlab Clinical's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	0	/	0.048
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(0.048 - 0)	/	0.048
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Medlab Clinical (ASX:MDC) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Medlab Clinical had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Medlab Clinical Gross Margin % Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medlab Clinical (ASX:MDC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (ASX:MDC) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11 Lord Street, Unit 5, Botany, NSW, AUS, 2019

Website

https://www.medlab.co

Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.